Roche/Corange
Executive Summary
Merger will occur by March 10, following approval from the Federal Trade Commission Feb. 24. FTC's approval requires Roche to proceed with its planned divestment of the thrombolytic Retavase to Centocor and to divest Boehringer Mannheim's CEDLA drug abuse testing line ("The Pink Sheet" Feb. 16, T&G-1)...